$QURE

Jacques Rachelle Suzanne sold $54K of QURE

Jacques Rachelle Suzanne sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Jacques Rachelle Suzanne
Published Jun 12, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings). No company-specific catalyst is included.

02

Market read

Traders may note the insider sale, but without additional company news it is unlikely to materially reset valuation or risk.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article provides no context for motive or whether other insiders are selling/buying concurrently.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-11.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure director Jacques Rachelle Suzanne sold 1,993 shares in an open-market transaction on 2026-06-11 at $27.06/share (Form 4).

Expected impact

Low near-term impact; any effect is likely short-lived unless followed by additional insider activity or company-specific catalysts.

Evidence & confidence

The filing is a standard director open-market sale with no 10b5-1 plan and no accompanying company event (earnings, guidance, deal, or regulatory action) in the text.

Market effects

No clear sector read-through; this is a single-company insider transaction with no disclosed operational/regulatory change.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted by some traders as less “mechanical,” potentially increasing short-term skepticism.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Jacques Rachelle Suzanne

    Director who sold 1,993 shares on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHigh

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

uniQure N.V. (QURE) shares rose over 20% after upgrades from Wells Fargo and RBC Capital Markets, citing improved regulatory prospects for its Huntington’s disease therapy, AMT-130. Wells Fargo raised its price target to $60, while RBC set it at $35, both noting the potential impact of an FDA official's departure. The FDA had previously requested additional trials, but analysts see a higher chance of approval.

$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.